Inactief instrument

Andere talen InspireMD Inc Nyse

Aandelen

US45779A8615

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M	14/05
InspireMD : Reports First Quarter 2024 Financial Results and Provides Business Update	14/05
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th	07/05
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024	26/03
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M	06/03
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	06/03
InspireMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th	28/02
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System	12/02
InspireMD Gets CE Mark Recertification From the European Union	31/01
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework	31/01
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America	03/01
InspireMD, Inc. Announces Appointment of Pete Ligotti as Executive Vice President and General Manager of North America	03/01
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System	20/12
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	27/11
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	27/11
Earnings Flash (NSPR) INSPIREMD Reports Q3 Revenue $1.6M	06/11
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update	06/11
InspireMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen InspireMD Inc Nyse

Aandelen

US45779A8615

Andere talen

Filters